Vedanta Biosciences, Inc news

• Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence
• Further CONSORTIUM study analysis shows that the VE303 high dose led to more robust colonization, which in turn correlated with prevention of recurrence
• Safety and colonization an

• High-dose VE303 in Phase 2 trial achieved primary endpoint, with 31.7% absolute risk reduction in rate of recurrence (or a greater than 80% reduction in the odds of a recurrence) at 8 weeks when compared with placebo
• Represents most advanced clinical trial of a rationally defined bacterial consortium candidate BARDA exercises $23.8 million option to support Phase 3 clinical trial of VE303, to initiate in 2022

• Results further support the benign safety profile of VE202 and identify an optimal dosing regimen
• Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021

Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal c